Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Shares Outstanding (Weighted Average): 2016-2025

Historic Shares Outstanding (Weighted Average) for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to $107.9 million.

  • Rocket Pharmaceuticals' Shares Outstanding (Weighted Average) rose 18.61% to $107.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.9 million, marking a year-over-year increase of 18.61%. This contributed to the annual value of $91.2 million for FY2024, which is 1.11% up from last year.
  • Rocket Pharmaceuticals' Shares Outstanding (Weighted Average) amounted to $107.9 million in Q3 2025, which was up 0.15% from $107.7 million recorded in Q2 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' Shares Outstanding (Weighted Average) peaked at $107.9 million during Q3 2025, and registered a low of $61.8 million during Q1 2021.
  • For the 3-year period, Rocket Pharmaceuticals' Shares Outstanding (Weighted Average) averaged around $92.4 million, with its median value being $90.8 million (2024).
  • Data for Rocket Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY increased of 23.01% (in 2023) over the last 5 years.
  • Over the past 5 years, Rocket Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarterly) stood at $64.4 million in 2021, then grew by 17.44% to $75.7 million in 2022, then grew by 19.12% to $90.2 million in 2023, then climbed by 1.11% to $91.2 million in 2024, then climbed by 18.61% to $107.9 million in 2025.
  • Its last three reported values are $107.9 million in Q3 2025, $107.7 million for Q2 2025, and $106.6 million during Q1 2025.